Business Context and Reporting Period
This Form 8-K is filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on November 22, 2022. The company is incorporated in Delaware and its common stock (Ticker: AGE) is listed on the NYSE American. The filing addresses a notice regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data. The primary financial metric disclosed is a regulatory requirement to increase stockholders' equity to not less than $4,000,000 to maintain listing status. No debt or liquidity figures are explicitly stated in this document.
Material Changes and Listing Status
- Compliance Plan Accepted: The NYSE American staff accepted a revised listing compliance plan from AgeX.
- Extension Granted: The company received an extension to regain compliance with Section 1003(a)(i) and (ii) of the Exchange Company Guide.
- Delisting Deadline: If the company fails to meet continued listing standards by May 17, 2023, or fails to make consistent progress, the Exchange will initiate delisting proceedings.
- Contingency Plan: AgeX intends to arrange for its common stock to be quoted on an electronic interdealer quotation system if delisted from the NYSE American.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements disclaiming any obligation to update future projections. The primary risk identified is the potential delisting from the NYSE American if the equity threshold is not met by the May 2023 deadline. The company notes that actual results may differ materially from anticipated results due to factors outlined in their periodic reports under "Risk Factors."
Investor Verification Checklist
- Verify the company's current stockholders' equity to assess progress toward the $4,000,000 threshold.
- Monitor subsequent filings for updates on the compliance plan milestones before the May 17, 2023 deadline.
- Confirm the trading status of the stock (AGE) on the NYSE American versus potential OTC markets.
- Review the attached press release (Exhibit 99.1) for additional context on the compliance strategy.